Pyxis Oncology Inc (NASDAQ: PYXS) kicked off on Monday, up 3.70% from the previous trading day, before settling in for the closing price of $1.62. Over the past 52 weeks, PYXS has traded in a range of $1.51-$6.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 41.24%. With a float of $41.13 million, this company’s outstanding shares have now reached $59.45 million.
The extent of productivity of a business whose workforce counts for 50 workers is very important to gauge. In terms of profitability, gross margin is 84.98%, operating margin of -343.24%, and the pretax margin is -293.15%.
Pyxis Oncology Inc (PYXS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Pyxis Oncology Inc is 30.83%, while institutional ownership is 51.89%. The most recent insider transaction that took place on Nov 26 ’24, was worth 174,364. In this transaction CFO & COO of this company bought 88,850 shares at a rate of $1.96, taking the stock ownership to the 1,199,143 shares.
Pyxis Oncology Inc (PYXS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 41.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.60% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Take a look at Pyxis Oncology Inc’s (PYXS) current performance indicators. Last quarter, stock had a quick ratio of 7.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.21 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
The latest stats from [Pyxis Oncology Inc, PYXS] show that its last 5-days average volume of 1.16 million was superior to 0.79 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 22.97%. Additionally, its Average True Range was 0.23.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 4.38%, which indicates a significant decrease from 27.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.46% in the past 14 days, which was lower than the 118.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.0921, while its 200-day Moving Average is $3.7779. Now, the first resistance to watch is $1.7312. This is followed by the second major resistance level at $1.7823. The third major resistance level sits at $1.8547. If the price goes on to break the first support level at $1.6077, it is likely to go to the next support level at $1.5353. The third support level lies at $1.4842 if the price breaches the second support level.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
The company with the Market Capitalisation of 106.47 million has total of 59,466K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -73,790 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -17,300 K.
